Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V4UO
|
|||
| Former ID |
DIB005267
|
|||
| Drug Name |
M-16209
|
|||
| Synonyms |
1-(3-Bromo-benzo[b]furan-2-ylsulfonyl)imidazolidine-2,4-dione; 1-(3-Bromobenzo[b]furan-2-ylsulfonyl)hydantoin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H7BrN2O5S
|
|||
| Canonical SMILES |
C1C(=O)NC(=O)N1S(=O)(=O)C2=C(C3=CC=CC=C3O2)Br
|
|||
| InChI |
1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
|
|||
| InChIKey |
ZJSUDHQFSBHLDV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 128851-36-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aldose reductase (AKR1B1) | Target Info | Inhibitor | [2], [3] |
| BioCyc | Methylglyoxal degradation III | |||
| Acetone degradation I (to methylglyoxal) | ||||
| KEGG Pathway | Pentose and glucuronate interconversions | |||
| Fructose and mannose metabolism | ||||
| Galactose metabolism | ||||
| Glycerolipid metabolism | ||||
| Metabolic pathways | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Fructose and Mannose Degradation | |||
| Pyruvate Metabolism | ||||
| Pterine Biosynthesis | ||||
| Glycerolipid Metabolism | ||||
| Galactose Metabolism | ||||
| WikiPathways | Metapathway biotransformation | |||
| Polyol Pathway | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000031) | |||
| REF 2 | Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.